Benign Prostatic Hyperplasia Treatment Market Growth Forecast Report 2030
(MENAFN- P&S Intelligence) In 2021, the BPH treatment market was worth around USD 11,892.8 million, and it is projected to advance at a 5.2% CAGR from 2021 to 2030, hitting USD 18,837.7 million by 2030, according to P&S Intelligence.
This growth can be credited to the growing favor for minimally invasive operations, the rising occurrence of BPH, and growing grants, investments, and funds for directing research on new treatments.
Operation is an improved substitute to the management of BPH through medicine, but patients are leaning more towards the medicine because of the post-surgery harm to the body done by surgical burns and cuts. The growth of minimally invasive techniques has brought an alteration in patients’ perceptions and given medical device manufacturers a competitive advantage.
In 2021, the drug category held the larger BPH treatment market share, of approximately 85%. This can be ascribed to the growing need for alpha-blockers as these medicines relax the muscle of the bladder neck and prostate, which allows urine to flow more simply.
Between the different kinds of medications, alpha-blockers have been extensively used to cure the illness in the past few years. Their growing usage and the abundance of medicines under development are current potential opportunities for the market.
With age in almost all men, BPH worsens. It can even cause bladder damage and infection, because of blood in the urine, and can be a sign of kidney damage. For its stoppage, several programs and campaigns are run internationally.
For example, in North America, each year, September is dedicated as National Prostate Health Month by health professionals, individuals, and health advocates worried with prostate health. The key purpose of titling an entire month for this body part is to spread knowledge regarding the danger factors and symptoms of the associated illnesses.
North America held the largest market share, of 41.0%, in 2021. The rising occurrence of the issue is boosting the acceptance of cutting-edge treatments, including prostatic stenting, laser therapy, and UroLift therapy, thus fuelling the market growth in the continent.
Additionally, the supportive reimbursement guidelines and an increasing number of skilled surgeons will aid the advance of the players in the continent in the coming few years.
The APAC region is projected to experience the fastest development in the coming few years, at a CAGR of 6.4%. The thriving disposable income and spending ability, rising living standards, growing urological illness burden, and increasing expenditure in the healthcare industry expand the progress.
Hence, growing favor for minimally invasive operations, rising occurrence of BPH, and growing grants, investments, and funds for directing research on new treatments are the major factors propelling the BPH treatment industry.
MENAFN05062023005304011875ID1106387223
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.